Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company business overview, accounting data, and financial indicators for the first half of 2024. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes sections such as "管理层讨论与分析" (Management Discussion and Analysis), financial statements, and other substantive financial and operational information. The document explicitly states it is a half-year report (半年度报告), which corresponds to an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification letter. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-29 Chinese
安旭生物2024年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled '2024 年限制性股票激励计划实施考核管理办法' which translates to '2024 Restricted Stock Incentive Plan Implementation Assessment Management Measures'. It details the company's internal rules and procedures for implementing and assessing a restricted stock incentive plan, including performance targets, assessment principles, responsibilities, and procedures. It references relevant laws and regulations but does not contain financial statements or earnings data. It is a governance-related document outlining the company's internal incentive plan management and assessment framework. It is not an announcement, report, or financial statement but a governance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is under 5,000 characters and contains detailed policy content, not just an announcement or summary, so it is not RPA or RNS.
2024-08-29 Chinese
安旭生物关于召开2024年第二次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a notice about convening the 2024 second extraordinary general meeting of shareholders for Hangzhou Anxu Biotechnology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders to attend and vote. It does not contain financial statements, audit results, or detailed financial data. It is an announcement related to a shareholders meeting rather than the meeting materials or results themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than solicitation materials or voting results, it is best classified as a Regulatory Filing (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is under 5,000 characters and is primarily an announcement of the meeting and voting process, not the meeting materials or results.
2024-08-29 Chinese
安旭生物关于2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) regarding the "2024年半年度募集资金存放与实际使用情况" which translates to "2024 Half-Year Report on the Storage and Actual Use of Raised Funds." It details the amount of funds raised, their storage, usage, management, and compliance with regulatory requirements. It includes detailed financial figures about fundraising, usage, and cash management for the half-year period ending June 30, 2024. The document references regulatory guidelines related to fundraising management and includes tables showing the use of funds in various projects. This is a specialized report focused on the use of capital raised by the company, not a general interim financial report or earnings release. It is not an announcement of a report publication but the report itself, given the length (over 10,000 characters) and detailed content. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage.
2024-08-29 Chinese
上海锦天城（杭州）律师事务所关于杭州安旭生物科技股份有限公司2024 年限制性股票激励计划的2024 年限制性股票激励计划的法律意见书
Regulatory Filings
2024-08-29 Chinese
安旭生物2024年限制性股票激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is titled "2024年限制性股票激励计划（草案）" which translates to "2024 Restricted Stock Incentive Plan (Draft)" for Hangzhou Anxu Biotechnology Co., Ltd. It extensively details the company's stock incentive plan, including the purpose, legal basis, management structure, scope of incentive recipients, stock quantities, pricing, vesting conditions, and performance targets. The document is a comprehensive plan related to equity incentives for employees and management, including directors and senior executives. It is not a financial report, earnings release, or regulatory filing about financial results or corporate governance changes. It is also not a proxy statement or voting results announcement. Instead, it is a detailed disclosure about a stock-based incentive plan, which is a capital/financing related update concerning the company's equity structure and employee compensation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement or summary, so it is not RPA or RNS. Confidence is high given the clear and detailed nature of the stock incentive plan document.
2024-08-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.